Doxorubicin induces drug efflux pumps in Candida albicans

Medical Mycology

Volumn 49, Issue 2, 2011, Pages 132-142

  Kofla, Grzegorz ^a   Turner, Vincent ^b   Schulz, Bettina ^a   Storch, Ulrike ^a   Froelich, Daniela ^a   Rognon, Bénédicte ^b   Coste, Alix T ^b   Sanglard, Dominique ^b   Ruhnke, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

ABC transporter; azoles; Candida albicans; doxorubicin; resistance mechanisms

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUCONAZOLE; MESSENGER RNA;

ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; CANCER CELL; CANCER THERAPY; CANDIDA ALBICANS; DRUG SENSITIVITY; EFFUSION; GENE EXPRESSION; HUMAN; NONHUMAN;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CANDIDA ALBICANS; CANDIDIASIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE TRANSPORT PROTEINS; POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION;

CANDIDA; CANDIDA ALBICANS;

EID: 78751504435     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.512022     Document Type: Article

References (33)

1. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29 : 239-244.
2. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans : frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31 : 327-332.
3. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39 : 309-317.
4. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37 : 1172-1177.
5. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 1071-1079
6. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11 : 382-402.
7. Sanglard D, Kuchler K, Ischer F, et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specifi c multidrug transporters. Antimicrob Agents Chemother 1995; 39 : 2378-2386.
8. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. C andida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47 : 2404-2412.
9. Franz R, Kelly SL, Lamb DC, et al. Multiple molecular mechanisms contribute to a stepwise development of fl uconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42 : 3065-3072.
10. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5 : 219-234.
11. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5 : 457-468.
12. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14 (Suppl. 1): 35-48.
13. Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990; 1 : 361-365.
14. Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007; 3 : 81-92.
15. Kofl a G, Ruhnke M. Development of a new real-time TaqMan PCR assay for quantitative analyses of Candida albicans resistance genes expression. J Microbiol Methods 2007; 68 : 178-183.
16. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3 : 1639-1652.
17. Rognon B, Kozovska Z, Coste AT, Pardini G, Sanglard D. Identifi cation of promoter elements responsible for the regulation of MDR1 from Candida albicans , a major facilitator transporter involved in azole resistance. Microbiology 2006; 152 : 3701-3722.
18. Franz R, Ruhnke M, Morschh?user J. Molecular aspects of fl uconazole resistance development in Candida albicans . Mycoses 1999; 42 : 453-458.
19. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14 : 643-658.
20. Rognon B, Kozovska Z, Coste AT, Pardini G, Sanglard D. Identifi cation of promoter elements responsible for the regulation of MDR1 from Candida albicans , a major facilitator transporter involved in azole resistance. Microbiology 2006; 152 : 3701-3722.
21. Uhl MA, Johnson AD. Development of S treptococcus thermophilus lacZ as a reporter gene for Candida albicans . Microbiology 2001; 1189-1195.
22. Coste A, Turner V, Ischer F, et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans . Genetics 2006; 172 : 2139-2156.
23. Pardini G, De Groot PW, Coste AT, et al. The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans . J Biol Chem 2006; 281 : 40399-40411.
24. Karababa M, Coste AT, Rognon B, Bille J, Sanglard D. Comparison of gene expression profi les of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother 2004; 48 : 3064-3079.
25. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungalsusceptibility testing of yeasts. Approved standard M27-A, 1997. Wayne, PA: National Committee for Clinical Laboratory Standards.
26. de Micheli M, Bille J, Schueller C, Sanglard D. A common drugresponsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol Microbiol 2002; 43 : 1197-1214.
27. Manoharlal R, Sharma M, Prasad R. Molecular determinants of transient and reversible induced up-regulation of CaCDR1 in azole susceptible clinical isolates of Candida albicans . Biosci Rep 2010 [in press]
28. Thakur JK, Arthanari H, Yang F, et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452 : 604-609.
29. Gregori C, Schuller C, Frohner IE, Ammerer G, Kuchler K. Weak organic acids trigger conformational changes of the yeast transcription factor War1 in vivo to elicit stress adaptation. J Biol Chem 2008; 25752-25764
30. O Keeffe J, Kavanagh K. Adriamycin alters the expression of drug effl ux pumps and confers amphotericin B tolerance in Candida albicans . Anticancer Res 2004; 24 : 405-408.
31. Henry KW, Cruz MC, Katiyar SK, Edlind TD. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob Agents Chemother 1999; 43 : 1968-1974.
32. Calvet HM, Yeaman MR, Filler SG. Reversible fl uconazole resistance in Candida albicans : a potential in vitro model. Antimicrob Agents Chemother 1997; 41 : 535-539.
33. Cowen LE, Sanglard D, Calabrese D, et al. Evolution of drug resistance in experimental populations of Candida albicans . J Bacteriol 2000; 182 : 1515-1522.